Core Viewpoint - NetraMark Holdings Inc. is uplisting to the Toronto Stock Exchange (TSX) from the Canadian Securities Exchange (CSE), which is expected to enhance its access to institutional investors and raise its profile in the capital markets [1][4]. Group 1: Uplisting Details - The common shares of NetraMark will be voluntarily delisted from the CSE effective February 17, 2026, and will commence trading on the TSX under the symbol "AIAI" on February 18, 2026 [1][2]. - The company will remain a "reporting issuer" under applicable Canadian securities laws during the transition from CSE to TSX [2]. Group 2: Company Strategy and Technology - The uplisting is seen as a significant milestone that reflects NetraMark's operational development and strengthens its positioning within capital markets as it advances the commercial adoption of its AI-powered platform, NetraAI [3][4]. - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, potentially increasing the likelihood of clinical trial success by avoiding overfitting [5]. - The company focuses on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to accurately segment diseases and classify patients [6].
Netramark Announces Uplisting to Toronto Stock Exchange